### DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled NITRIC OXIDE DONOR COMPOSITION AND METHOD FOR TREATMENT OF ANAL DISORDERS, the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed: NONE

I hereby claim the benefit under Title 35, United States Code, 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application: U.S. Application Serial No. 08/250,555, filed May 27, 1994 and entitled "A Pharmacological Preparation for the Treatment of Anal Disorders".

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and to file and prosecute any corresponding foreign applications, including any international applications under the Patent Cooperation Treaty or the European Patent Convention: J. David Wharton, Reg. No. 25,717; Don M. Bradley, Reg. No. 22,412; Michael B. Hurd, Reg. No. 32,241; Joan Optican Herman, Reg. No. 31,968; Patrick A. Lujin, Reg. No. 35,260; Michael J. Gross, Reg. No. 35,528; and D. Bartley Eppenauer, Reg. No. 35,499, telephone number (816) 474-6550. Address all correspondence to: SHOOK, HARDY & BACON P.C., One Kansas City Place, 1200 Main Street, Kansas City, Missouri 64105-2118.

10983861

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Inventor's signature:

Stephen R. Gorfine Da

Residence: Citizenship: Post Office Address: New York county, New York United States of America 1215 Fifth Avenue New York, New York 10029

# tootis. Tootis

# CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Applicant: GORFINE, Stephen R.			
Application No. 08/970,447 Filed: November 14, 1997			
For: NITRIC OXIDE DONOR COMPOSITION FOR TREATMENT OF ANAL DISORDERS			
CELLEGY PHARMACEUTICALS INC. , a CORPORATION  (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)			
certifies that it is assignee of the patent application identified above by virtue of either:			
A. [ ] An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.  OR			
B. [X] A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:			
1. From: Stephen R. Gorfine To: Neptune Pharmaceutical Corporation The document was recorded in the Patent and Trademark Office at Reel 7374, Frame 0516, or for which a copy thereof is attached.			
2. From: Neptune Pharmaceutical Corporation To: Cellegy Pharmaceuticals, Inc.  The document was recorded in the Patent and Trademark Office at  Reel, Frame, or for which a copy thereof is attached.			
[ X ] Copies of assignments or other documents in the chain of title are attached.			
The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee			
I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.			
Date: February 23 1998  Name: Michael L! Francocur			
Name: Michael L. Francocu			
Title : VF KYT			
Signature:			

### PATENT ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "ASSIGNOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Cellegy Pharmaceuticals, Inc., a California corporation, having a place of business at 1065 East Hillsdale Boulevard, Suite 418, Foster City, CA 94404 ("ASSIGNEE"), for itself and its successors, transferces, and assignees, the entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in United States Letters Patent listed on Schedule A strached hereto and the patent applications listed on Schedule B attached hereto, together with any reissue, extension, improvement, division, continuation or continuation-in-part of any thereof, in the U.S. or worldwide, and all rights of priority resulting from the filing in the United States of the patents or patent applications identified on Schedule A or B.

ASSIGNOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own pane.

ASSIGNOR agrees to do the following, when requested, and withour further consideration, in order to carry out the intent of this Assignment: (1) execute all onths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall reasonably consider desirable for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature

Date of Signature

Neptume Pharmaceutical Corporation

By Linkar P. Signature

By Linkar P. Signature

December 30, 1997

December 30, 1997

December 30, 1997

Callegy-Neptime Asset Parchase Agreement

Some of New York	•
County of Men York	
an amazactury evidence to be the person whose selection evidence to the selection whose selections are that (he/she) executed the	reconally known to me or proved to me on the basis to name is subscribed to the within instrument and a same in [his/her] authorized capacity, and that by on, or the emity upon behalf of which the person
Notary Scal  NRIA L. KUSCSK  Notary Public. State of New York  No. 4602348  Outsified in Suffolk Courtey VAN 31,119	Mine L. Kuscock
	· ·

### SCHEDULEA

Patents

Country	Patent No.	Date of Patent	Title
U.S.A.	<b>5,50</b> 4,117	<b>4/2</b> /96	Pharmacologic Preparation for the Treatment of Anal Disorders
U.S.A.	<b>5,69</b> 3,676	1 <b>2/2/97</b>	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders

# SCHEDULE B

# Parent Applications

Country	Serial/Appl. No.	Filine Date	Title
Israi	113,448	4/20/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
China	95190687.9	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Korea	700442/1996	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Mexico	960386	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Singapore	<b>9600</b> 491-6	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Canada	2168247	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Japan	500835/96	4/10/95	Nimic Oxide Donor Composition and Method for Treatment of Anal Disorders
EPC	95916264.5	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
U.S.A.	0 <b>8/</b> 970,447	11/14/97	Nitric Oxide Donor Composition for Treatment of Anal Disorders

UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS 004520 6 Washington, D.C. 20231

MAY 27, 1998

PTAS

TOWNSEND AND TOWNSEND AND CREW LLP MARGARET A. POWERS TWO EMBARCADERO CENTER, 8TH FLOOR SAN FRANCISCO, CA 94111-3834



UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM CORY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELCW. IT;

<u></u> PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE Information contained on this recordation notice reflects the data $\Box$ PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 03/27/1998

REEL/FRAME: 9052/0861

NUMBER OF PAGES: 6

ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

L

NEPTUNE PHARMACEUTICAL CORPORATION DOC DATE: 12/31/1997

ASSIGNEE:

CELLEGY PHARMACEUTICALS, INC. 1065 EAST HILLSDALE BOULEVARD, SUITE 418

FOSTER CITY, CALIFORNIA 94404

SERIAL NUMBER: 08970447

PATENT NUMBER:

FILING DATE: 11/14/1997

ISSUE DATE:

SERIAL NUMBER: 08250555

PATENT NUMBER: 5504117

FILING DATE: 05/27/1994 ISSUE DATE: 04/02/1996

SERIAL NUMBER: 08666264

FILING DATE: 06/20/1996

PATENT NUMBER: 5693676 ISSUE DATE: 12/02/1997 MAYA BENNETT, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

LOOPLIGH LETTOL



 Additional name(s) of conveying party(ies): (Continued from Page 1)

2. Additional name(s) and address(es) of receiving party(ies): (Continued from Page 1)

 Additional application number(s) or patent number(s): (Continued from Page 1)

A. Patent Application No.(s)

B. Patent No.(s)

5,693,676

### PATENT ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "ASSIGNOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to Cellegy Pharmaceuticals, Inc., a California corporation, having a place of business at 1065 East Hillsdale Boulevard, Suite 418, Foster City, CA 94404 ("ASSIGNEE"), for itself and its successors, transferrees, and assignees, the entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in United States Letters Patent listed on Schedule A strached hereto and the patent applications listed on Schedule B attached hereto, together with any reissue, extension, improvement, division, continuation or continuation-in-part of any thereof, in the U.S. or patent applications identified on Schedule A of B.

ASSIGNOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

ASSIGNOR agrees to do the following, when requested, and withour further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall reasonably consider desirable for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. ASSIGNOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE heretunder.

ASSIGNOR represents that ASSIGNOR has the rights, titles, and interests to convey as set forth herein, and coverants with ASSIGNEE that ASSIGNOR has made or will make hereafter no assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature

Date of Signature

Neptume Pharmaceutical Corporation

By Signature

Signature

Signature

Signature

Executed By This Person

Signature

December 10, 1997

December 30, 1997

December 30, 1997

### **SCHEDULE A**

Patents

Country	Patent No.	Date of Patent	Title
U.S.A.	5,504,117	4/2/95	Pharmacologic Preparation for the Treatment of Anal Disorders
U.S.A.	5 <b>,6</b> 93,676	12/2/97	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders

# SCHEDULE B

# Patent Applications

Country	Secial/Appl. No.	Filine Date	Title
Israel	113,448	4/20/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
China	95190687.9	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Korea	700442/1996	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Mexico	960386	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Singspore	<del>96004</del> 91-6	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
Canada	2168247	4/10/95	Nitric Oxide Donor Composition and Method for Treatment of Anal Disorders
Japan	S00835/96	4/10/95	Nime Oxide Donor Composition and Method for Treatment of Anal Disorders
EPC	95916264.5	4/10/95	Nitrie Oxide Donor Composition and Method for Treatment of Anal Disorders
U.S.A.	08/970,447	11/14/97	Nitric Oxide Danor Composition for Treatment of Anal Disorders

	On De com Ger 31, 1967 before ma personali	ŗ
	appeared <u>Titohen R. Gothine</u> personally known to me or proved to me on the basi	8
	of satisfactory evidence to be the person whose name is subscribed to the within instrument an	đ
	zeknowledged to me that (he/she) executed the same in [his/her] authorized capacity, and that b	y
	[his/her] signature on the instrument the person, or the entity upon behalf of which the person	n
	noted, executed the instrument.	
<u>ļ</u>	Mine L. Kuswit	
	Notary Scal Nina L. Kuscsik Natury	
'ema' 	Notary Public, State of New York	
	Na 4602340	
14	Qualified in Suffolk Courtey JAN 31,1/94	
<u>į</u>		
į.		
T		
Ŋ		
ij		
in.		
T.		
<u>ļ</u>		

Some of New York Country of New York





FORM PTO-1595

	(Rev. 6-93)	100676211	SHEET Patent and Trademark Office	
	To the Honorable Asst. Commissioner for	Patents. Please reco	ord the attached original documents or copy thereof.	
0)-	1. Name of conveying party(ies):		2. Name and address of receiving party(ies):	
7.5	Neptune Pharmaceutical Corporation		Name: Cellegy Pharmaceuticals, Inc.	
111160	Additional name(s) of conveying party(ies) attached?	Yes X No	Internal Address:	
			Street Address: 1065 East Hillsdale Boulevard, Suite 418	
	3. Nature of conveyance:		The state of the s	
	x Assignment Merger		City: Foster City State: Chifornia ZiP: 94404	
	Security Agreement C	hange of Name	MAR 2 7 1998 RECEIPT ACCIONS DIV	
	Execution Date: December 31, 1997		·	
			Additional name(s) & address(es) attached? Yes X No	
		with a new application	on, the execution date of the application is:	
ł	A. Patent Application No.(s) 08/97	0,447	B. Patent No.(s) 5,504,117	
	Addi	tional numbers attac	hed? X Yes No	
	5. Name and address of party to whom concerning document should be mailed:	prrespondence	6. Total number of applications and patents involved: 3	
١	Name: Margaret A. Powers		7. Total fee (37 CFR 3.41): \$ 120.00	
	TOWNSEND and TOWNSEND and Two Embarcadero Center, 8th Flor San Francisco, California 94111-3	or 3834	Enclosed X Charge Fees to Deposit Account	
	(650) 326-2400		Charge any additional fees associated with this paper or during the pendency of this application, or credit any overpayment, to deposit account	
	$\sim$		8. Deposit account number: 20-1430	
08	/1998 SSHITH 00000090 201430 08970447			
FQ FQ	:581 40.00 CH :581 60.00 CH	DO NOT US	E THIS SPACE	
_	9. Statement and signature.			
	To the best of my knowledge and believe of the original document.	f, the foregoing info	mation is true and correct and any attached copy is a true copy	
Margaret A. Powers March 23, 1998				
Name of Person Signing  Atty. Reg. No. 39,804  Total number of pages including cover sheet, attachments, and document:  10. Change Correspondence Address to that of Part 5? X Yes No				
			cs IIII	
OMB No. 0651-0011 (exp. 4/94)				
Do not detach this portion  Mail documents to be recorded with required cover sheet information to:  Asst. Commissioner for Patents  Box Assignments  Weshington, D. C. 20231				
-		AA garmidtou	, U.U. ZUZO I	